Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-CD20 therapies and pregnancy in neuroimmunologic disorders
Tania Kümpfel, Sandra Thiel, Ingrid Meinl, et al.
Neurology Neuroimmunology & Neuroinflammation (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
Tania Kümpfel, Katrin Giglhuber, Orhan Aktaş, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 141-176
Open Access | Times Cited: 82
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
de Sèze, Élisabeth Maillart, Antoine Guéguen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 69
Family planning considerations in people with multiple sclerosis
Kristen M. Krysko, Ruth Dobson, Raed Alroughani, et al.
The Lancet Neurology (2023) Vol. 22, Iss. 4, pp. 350-366
Open Access | Times Cited: 66
Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
Kerstin Hellwig, Marianne Tokic, Sandra Thiel, et al.
JAMA Network Open (2022) Vol. 5, Iss. 1, pp. e2144750-e2144750
Open Access | Times Cited: 53
Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines
Bassem Yamout, Mohammed Aljumah, Mohammad Ali Sahraian, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 83, pp. 105435-105435
Closed Access | Times Cited: 12
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Wei Zhen Yeh, Putu Ayu Widyastuti, Anneke van der Walt, et al.
Neurology (2021) Vol. 96, Iss. 24
Open Access | Times Cited: 54
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
Serena Brancati, Lucia Gozzo, Laura Longo, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 48
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Carmen Tur, Anne‐Laure Dubessy, Susana Otero‐Romero, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 9, pp. 1424-1456
Open Access | Times Cited: 34
Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
Mingchao Shi, Fengna Chu, Tao Jin, et al.
CNS Neuroscience & Therapeutics (2022) Vol. 28, Iss. 7, pp. 981-991
Open Access | Times Cited: 33
Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines
Ruth Dobson, David Rog, Caroline Ovadia, et al.
Practical Neurology (2022) Vol. 23, Iss. 1, pp. 6-14
Open Access | Times Cited: 33
Neonatal B-Cell Levels and Infant Health in Newborns Potentially Exposed to Anti-CD20 Monoclonal Antibodies During Pregnancy or Lactation
Carolin Schwake, Julia Steinle, Sandra Thiel, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 4
Open Access | Times Cited: 6
Pregnancy and autoimmune disease: diseases of the nervous system, connective tissue, and the bowel
Waltraut M. Merz, Rebecca Fischer‐Betz, Kerstin Hellwig, et al.
Deutsches Ärzteblatt international (2022)
Open Access | Times Cited: 24
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
Kerstin Hellwig, Marianne Tokic, Sandra Thiel, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 4
Open Access | Times Cited: 15
Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
Isabella Laura Simone, Carla Tortorella, Alma Ghirelli
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 29
Adverse Events in NMOSD Therapy
Katrin Giglhuber, Achim Berthele
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4154-4154
Open Access | Times Cited: 22
Use of B-Cell–Depleting Therapy in Women of Childbearing Potential With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
Alexandra Galati, Thomas F. McElrath, Riley Bove
Neurology Clinical Practice (2022) Vol. 12, Iss. 2, pp. 154-163
Open Access | Times Cited: 19
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2
Jessica Shipley, James Beharry, Wei Zhen Yeh, et al.
The Medical Journal of Australia (2025)
Closed Access
Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations
Andrea Pluma, Sabrina Hamroun, Linda Rüegg, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Cladribine and pregnancy in women with multiple sclerosis: The first cohort study
Karen Dost-Kovalsky, Sandra Thiel, Andrea I. Ciplea, et al.
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 3, pp. 461-465
Closed Access | Times Cited: 18
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
Wei Zhen Yeh, Anneke van der Walt, Olga Skibina, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 6
Open Access | Times Cited: 3
Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder
Liang Wang, Manqiqige Su, Zhirui Zhou, et al.
JAMA Network Open (2022) Vol. 5, Iss. 8, pp. e2225438-e2225438
Open Access | Times Cited: 16
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
Sarah Demortière, Adil Maarouf, Audrey Rico, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 9
A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD)
Maria Isabel Leite, Zoya Panahloo, Niall Harrison, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 75, pp. 104760-104760
Closed Access | Times Cited: 8
The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results
Sandra Thiel, Andrea I. Ciplea, Ralf Gold, et al.
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 20
Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
Shin Yee Chey, Allan G. Kermode
Multiple Sclerosis Journal - Experimental Translational and Clinical (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top